Market Data
Market Cap₹14,832.09 Cr.
52W High₹1,226.1
Current Price₹828.1
52W Low₹789.3
Down from 52W High32.5 %
Face Value₹2
Performance
ROCE11.59 %
ROE12.41 %
EPS (TTM)₹11.53
EPS Prev Qtr₹14.96
EPS Last Year₹28.94
EBITDA Qtr₹139.4 Cr.
Book Value₹514
Financial Health
Debt/Equity0.08
Debt/Profit0.7
Total Assets₹11,073.7 Cr.
Dividend Yield0.6 %
Promoter Holding49.42 %
Earning Power7.73 %
Valuation
Stock P/E12.96
Industry P/E33.81
Price to Book1.61
Price to Sales4.26
Graham Number₹859.88
Key Metrics
__derived
1
Dividend/Share
₹1.5
Face Value
₹2
About Natco Pharma Ltd
Healthcare · Pharmaceuticals
Natco Pharma Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹2. Market cap ₹14,832.09 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a healthy ROCE of 14.61%, indicating efficient use of capital.
- ROE stands at 13.33%, reflecting strong returns on shareholders' equity.
- The company maintains a low debt-to-equity ratio of 0.04, suggesting a conservative capital structure.
- Promoter holding is at 49.42%, indicating significant management control and alignment of interests.
- The company offers a dividend yield of 0.6% with a dividend per share of ₹1.5, providing some income to investors.
Weaknesses
- The P/E ratio of 12.98 may be considered relatively high for the pharmaceutical sector, potentially indicating overvaluation.
- The P/B ratio of 1.95 suggests the market values the company at a premium over its book value.
- The dividend yield of 0.6% is relatively low, which might not attract income-focused investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue fell 44.7% YoY, Profit fell 74.6% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 1,328.9 | 1,363 | 647.3 | 739.1 | 735.2 |
| ↳ QoQ Growth | - | +2.6% | -52.5% | +14.2% | -0.5% |
| Expenses | 815.5 | 836.2 | 534.8 | 661.9 | 595.8 |
| Operating Profit | 513.4 | 526.8 | 112.5 | 77.2 | 139.4 |
| OPM % | 38.63% | 38.65% | 17.38% | 10.45% | 18.96% |
| Other Income | 61.7 | 100 | 58.1 | 77.8 | 59.2 |
| Interest | 3.2 | 13.1 | 9.5 | 10.9 | 13 |
| Depreciation | 57.6 | 52.4 | 46.2 | 50.4 | 47.1 |
| EBITDA | 571 | 579.2 | 158.7 | 127.6 | 186.5 |
| EBITDA Margin % | 42.97% | 42.49% | 24.52% | 17.26% | 25.37% |
| Profit Before Tax | 571.9 | 613.7 | 161.1 | 144.1 | 185.6 |
| Tax % | 16.02% | 15.61% | 12.85% | -61.9% | 34.16% |
| Net Profit | 480.3 | 517.9 | 140.4 | 233.3 | 122.2 |
| ↳ QoQ Growth | - | +7.8% | -72.9% | +66.2% | -47.6% |
| EPS | 26.84 | 28.94 | 8.46 | 14.96 | 11.53 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 4078.3 | 3484.6 |
| Expenses | 2848.4 | 2628.7 |
| Operating Profit | 1229.9 | 855.9 |
| OPM % | 30.16% | 24.56% |
| Other Income | 297.6 | 295.1 |
| Interest | 36.7 | 46.5 |
| Depreciation | 206.6 | 196.1 |
| Profit Before Tax | 1490.8 | 1104.5 |
| Tax % | 7.98% | 8.21% |
| Net Profit | 1371.9 | 1013.8 |
| EPS | 79.2 | 63.89 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
3.8%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
10.99%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 35.8 | 35.8 |
| Reserves | 7571.2 | 9185.3 |
| Borrowings | 279.4 | 706.4 |
| Other Liabilities | 744.4 | 1146.2 |
| Total Liabilities | 8630.8 | 11073.7 |
| Fixed Assets | 2431.9 | 2802.7 |
| CWIP | 225.4 | 293.7 |
| Investments | 473.6 | 3127.1 |
| Other Assets | 5499.9 | 4850.2 |
| Total Assets | 8630.8 | 11073.7 |
Cash Flows
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity | 1696.8 | 1768.3 |
| Cash from Investing Activity | -1414.5 | -2081.7 |
| Cash from Financing Activity | -210.7 | 297.5 |
| Net Cash Flow | 71.6 | -15.9 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 927.85 |
| ROCE % | 11.86% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 49.48% | 49.48% | 49.42% | 49.42% |
| FIIs % | 14.09% | 15.16% | 17.37% | 16.99% |
| DIIs % | 5.88% | 5.39% | 5.46% | 5.62% |
| Public % | 25.84% | 25.38% | 23.34% | 23.41% |
| No. of Shareholders | 4,19,699 | 4,24,167 | 4,10,970 | 4,03,166 |
Major Shareholders (>1%)
- V C NannapaneniPromoter and Promoter Group15.66%
- Time Cap Pharma Labs Private LimitedPromoter and Promoter Group9.59%
- Venkata Satya Swathi KantamaniPromoter and Promoter Group8.90%
- Natsoft Information Systems Pvt LtdPromoter and Promoter Group8.81%
As of 2026-06-30View all shareholders →